Sign in Subscribe
Class action lawsuits

Novo Nordisk A/S Faces Class Action Over Misrepresented Revenue and Profit Growth Potential

Strategic Insights

— 1 min read

Stockholders of Novo Nordisk A/S, a healthcare company focused on research, development, manufacturing, and distribution of pharmaceuticals, are being reminded of a class action lawsuit filed on their behalf regarding alleged misrepresentations of revenue and profit growth potential. The complaint, filed between May 7, 2025, and July 28, 2025, claims that Novo Nordisk's representations regarding its growth potential were overstated, and the company failed to account for the impact of the personalization exception to the compounded GLP-1 exclusion.

Key Takeaways:

  • The class action lawsuit alleges that Novo Nordisk misrepresented its revenue and profit growth potential, which led to the decline in the company's stock price from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025.
  • The lawsuit claims that the company failed to disclose that its growth potential was overstated and failed to account for the impact of the personalization exception to the compounded GLP-1 exclusion.
  • Novo Nordisk announced that it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025, attributing the guide down to lowered growth expectations for the second half of 2025.
  • Shareholders who want to serve as lead plaintiff for the class must submit their papers with the court by September 30, 2025.
  • The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • Shareholders who choose to take no action can remain an absent class member.

Statistics:

  • The price of Novo Nordisk's common stock declined from $69.00 per share on July 28, 2025 to $53.94 per share on July 29, 2025.
  • The class action lawsuit was filed between May 7, 2025, and July 28, 2025.
  • Shareholders who want to serve as lead plaintiff must submit their papers with the court by September 30, 2025.

Sources:

  • PRNewswire, "Novo Nordisk A/S (NVO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit & File a Lead Plaintiff by September 30, 2025 (NVO)".

Read more